<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02637076</url>
  </required_header>
  <id_info>
    <org_study_id>017-2014</org_study_id>
    <nct_id>NCT02637076</nct_id>
  </id_info>
  <brief_title>Xyrem and Brain Dopamine in Narcolepsy</brief_title>
  <official_title>Does Xyrem Influence Brain Dopamine in Patients With Narcolepsy? A PET Imaging Investigation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre for Addiction and Mental Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre for Addiction and Mental Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall aim of this investigation is to establish whether an action of Xyrem速 on the
      brain dopamine system in patients with narcolepsy, and in a comparison control group, might
      explain part of the anti-narcoleptic effect of the drug.

      Trial Objective is to establish, using positron emission tomography (PET), in Xyrem速-na誰ve
      narcolepsy with cataplexy patients, and in matched controls, whether a single dose of Xyrem速
      causes changes in striatal binding of 11C-raclopride and 11C-DTBZ that would suggest altered
      activity of brain dopamine neurones.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Actual">January 23, 2020</completion_date>
  <primary_completion_date type="Actual">January 23, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Participants will be recruited to fill 2 separate study groups: 1) participants with a diagnosis of narcolepsy with cataplexy; 2) healthy controls.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in PET 11C-raclopride binding from baseline to 7 hours post Xyrem</measure>
    <time_frame>7 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood gamma-hydroxybutyrate (GHB) concentration</measure>
    <time_frame>multiple time points from 0 to 7 hours post-Xyrem</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Narcolepsy With Cataplexy</condition>
  <arm_group>
    <arm_group_label>narcolepsy with cataplexy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients given single dose of Xyrem</description>
  </arm_group>
  <arm_group>
    <arm_group_label>health controls</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>healthy controls given a single dose of Xyrem</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Xyrem</intervention_name>
    <description>single 3.0 gram dose</description>
    <arm_group_label>health controls</arm_group_label>
    <arm_group_label>narcolepsy with cataplexy</arm_group_label>
    <other_name>Sodium Oxybate</other_name>
    <other_name>gamma-hydroxybutyrate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  current diagnosis of narcolepsy with cataplexy OR healthy control

        Exclusion Criteria:

          -  use of any sedative hypnotics, tranquilizers, anticonvulsants, antihistamines (except
             non-sedating), benzodiazepines, clonidine or any medication known to affect dopamine
             at start of baseline period

          -  significant unstable or uncontrolled medical/psychiatric disease

          -  significant history of head trauma/surgery or seizure disorder

          -  radiation exposure exceeding 20mSv in last 12 months

          -  pregnancy

          -  substance abuse/dependence (including alcohol)

          -  have sleep apnea, or are shift workers

          -  on a sodium-restricted diet

          -  has ever taken Xyrem / sodium oxybate / GHB at any time

          -  claustrophobia

          -  metal implants / objects in the body that may interfere with MRI

          -  succinic semialdehyde dehydrogenase deficiency
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen J Kish, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre for Addiction and Mental Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre for Addiction and Mental Health (CAMH)</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5T 1R8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>December 17, 2015</study_first_submitted>
  <study_first_submitted_qc>December 18, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 22, 2015</study_first_posted>
  <last_update_submitted>January 23, 2020</last_update_submitted>
  <last_update_submitted_qc>January 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centre for Addiction and Mental Health</investigator_affiliation>
    <investigator_full_name>Stephen Kish</investigator_full_name>
    <investigator_title>Senior Scientist, Head Human Brain Lab</investigator_title>
  </responsible_party>
  <keyword>Xyrem</keyword>
  <keyword>narcolepsy with cataplexy</keyword>
  <keyword>positron emission tomography</keyword>
  <keyword>dopamine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Narcolepsy</mesh_term>
    <mesh_term>Cataplexy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sodium Oxybate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

